Series A · Biotech · Lausanne, Switzerland · Founded 2019 · 24–30 employees
HAYA Therapeutics is pioneering precision RNA-guided therapeutics that target the dark genome to reprogram disease-driving cell states. The company develops drugs targeting long non-coding RNAs (lncRNAs) that regulate cellular processes, focusing initially on cardiac fibrosis and heart failure. Their lead candidate HTX-001 targets Wisper, a cardiac-specific lncRNA, and is advancing toward Phase 1 clinical trials. The company secured a landmark $1 billion collaboration with Eli Lilly for obesity applications and raised $65 million in Series A funding in May 2025. HAYA won the top prize at the TOP 100 Swiss Startup Award 2023 and represents a breakthrough approach to treating chronic and age-related diseases by addressing root causes rather than symptoms.